A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures

被引:92
作者
Desloovere, K
Molenaers, G
Jonkers, I
De Cat, J
De Borre, L
Nijs, J
Eyssen, M
Pauwels, P
De Cock, P
机构
[1] Univ Hosp Leuven, UZ Pellenberg, Gait Anal Lab, B-3212 Pellenberg, Belgium
[2] Univ Hosp Leuven, Dept Orthopaed Surg, B-3212 Pellenberg, Belgium
[3] Univ Hosp Leuven, Dept Neuropaediat, B-3212 Pellenberg, Belgium
[4] Univ Hosp Leuven, Dept Rehabil, B-3212 Pellenberg, Belgium
[5] Katholieke Univ Leuven, Dept Phys Therapy, Louvain, Belgium
关键词
botulinum toxin type A; casting; cerebral palsy; gait analysis;
D O I
10.1046/j.1468-1331.2001.00040.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It is recognized that objective gait analysis is of great value in planning a multilevel botulinum toxin type A (BTX-A) treatment, After BTX-A treatment. objective outcome measures can provide new and interesting information for each individual child with cerebral palsy (CP). Moreover, by studying group results, we may evaluate our treatment hypotheses. The present prospective study attempts to document the effect of integrated multilevel BTX-A treatment on objective gait parameters and to define the optimal strategy for the combined treatment of BTX-A with casting in children with cerebral palsy. Objective three-dimensional gait analysis (3DGA) data were collected pre- and 2 months post-treatment, in two randomized patient groups: a first group of 17 children treated with lower leg casting prior to BTX-A injections. and a second group or 17 patients who received casting immediately after injections. The present study demonstrates that improved gait can be achieved after a multilevel BTX-A treatment. combined with casting, using a set of 90 gait parameters. The most pronounced improvement was seen at the ankle joint, The results in the knee., hip and pelvis imply that multilevel treatment of the child with CP should start at an early age. in order to prevent development of muscle contractures. Slightly more pronounced benefits. mainly in the proximal joints, were seen for the children who were casted after injections as compared to the children who were casted before injections.
引用
收藏
页码:75 / 87
页数:13
相关论文
共 27 条
[1]  
[Anonymous], 1996, GAIT POSTURE
[2]  
Boyd R, 1997, EUR J NEUROL, V4, pS15
[3]   Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy [J].
Boyd, RN ;
Pliatsios, V ;
Starr, R ;
Wolfe, R ;
Graham, HK .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2000, 42 (01) :32-41
[4]  
BOYD RN, IN PRESS DEV MED CHI
[5]   BOTULINUM TOXIN-A IN MANAGEMENT OF CEREBRAL-PALSY [J].
CALDERONGONZALEZ, R ;
CALDERONSEPULVEDA, R ;
RINCONREYES, M ;
GARCIARAMIREZ, J ;
MINOARANGO, E .
PEDIATRIC NEUROLOGY, 1994, 10 (04) :284-288
[6]   Botulinum toxin A in hamstring spasticity [J].
Corry, IS ;
Cosgrove, AP ;
Duffy, CM ;
Taylor, TC ;
Graham, HK .
GAIT & POSTURE, 1999, 10 (03) :206-210
[7]   Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: A randomised prospective trial [J].
Corry, IS ;
Cosgrove, AP ;
Duffy, CM ;
McNeill, S ;
Taylor, TC ;
Graham, HK .
JOURNAL OF PEDIATRIC ORTHOPAEDICS, 1998, 18 (03) :304-311
[8]  
COSGROVE AP, 1994, DEV MED CHILD NEUROL, V36, P386
[9]   Hamstrings and psoas lengths during normal and crouch gait: Implications for muscle-tendon surgery [J].
Delp, SL ;
Arnold, AS ;
Speers, RA ;
Moore, CA .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1996, 14 (01) :144-151
[10]  
Desloovere K, 2000, GAIT POSTURE, V12, P57